Education
About Us
Working with TipRanks
Follow Us
Plant Advanced Technologies SA (FR:ALPAT)
:ALPAT
Top Page
Plant Advanced Technologies SA
(ALPAT)
Select Model
Select Model
Rating:59Neutral
Price Target:
€8.50
▲(3.41% Upside)
The score is primarily supported by improved 2024 financial performance, particularly the profitability rebound and strong positive free cash flow. This is offset by weak technicals (price below major moving averages with negative MACD and sub-50 RSI) and limited valuation support due to a negative P/E and no stated dividend yield.
Plant Advanced Technologies SA (ALPAT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€8.54M
Dividend YieldN/A
Average Volume (3M)388.00
Price to Earnings (P/E)―
Beta (1Y)-0.04
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,122,001
10 Day Avg. Volume379
30 Day Avg. Volume388
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.44
Price to Sales (P/S)6.86
P/FCF Ratio6.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Plant Advanced Technologies SA Business Overview & Revenue Model
Company DescriptionPlant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. The company was founded in 2005 and is headquartered in Vanduvre-lès-Nancy, France.
How the Company Makes Money
Plant Advanced Technologies SA Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34M | 1.93M | 1.68M | 2.34M | 2.31M | 1.72M |
| Gross Profit | -4.65M | 2.24M | 2.15M | -4.65M | -2.73M | -2.82M |
| EBITDA | -744.00K | 956.45K | 72.53K | -744.00K | -1.27M | -819.00K |
| Net Income | -849.00K | 935.13K | 79.17K | -849.00K | -1.13M | -543.00K |
Balance Sheet | ||||||
| Total Assets | 17.08M | 16.00M | 14.91M | 17.08M | 17.11M | 17.27M |
| Cash, Cash Equivalents and Short-Term Investments | 669.00K | 79.70K | 0.00 | 669.00K | 2.49M | 3.26M |
| Total Debt | 5.97M | 3.42M | 4.36M | 5.97M | 6.14M | 5.73M |
| Total Liabilities | 10.29M | 6.83M | 6.78M | 10.29M | 9.73M | 8.73M |
| Stockholders Equity | 5.50M | 9.17M | 8.13M | 5.50M | 6.36M | 7.53M |
Cash Flow | ||||||
| Free Cash Flow | -1.20M | 2.08M | 972.53K | -479.00 | -504.00 | -499.00 |
| Operating Cash Flow | -449.82K | 2.50M | 1.85M | -274.00 | -388.00 | 78.00 |
| Investing Cash Flow | -724.25K | -1.59M | -1.28M | -1.97K | -1.11K | -1.18K |
| Financing Cash Flow | 107.14K | -585.89K | -851.03K | 244.00 | 743.00 | 2.38K |
Plant Advanced Technologies SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALPAT
Plant Advanced Technologies SA
7.64
-4.16
-35.25%
DE:3HB
Hybrigenics SA Class A
―
―
―
DE:0N6A
TME Pharma N.V.
0.06
-0.01
-14.49%
DE:8JD
Valbiotis SA
0.72
-0.85
-53.95%
DE:3VG
Theranexus SA
2.08
1.54
285.19%
DE:82F
NFL Biosciences SA
1.25
-0.52
-29.41%
Plant Advanced Technologies SA Corporate Events
Plant Advanced Technologies SA Reports H1 2025 Results with Optimistic Outlook
Nov 3, 2025
Plant Advanced Technologies SA reported a net loss of 162 k€ for the first half of 2025, with revenue at 155 k€, reflecting the seasonal nature of its business and exclusion of ongoing R&D contract revenues. Despite this, the company remains optimistic about achieving positive results for the third consecutive year, driven by portfolio diversification and CSR commitments. Operational highlights include advancements in cosmetics, pharmaceuticals, agrochemicals, and nutraceuticals, with promising developments in active ingredients and dietary supplements.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.